Mintz advised Immunome, and Cooley and Goodwin advised Morphimmune. Immunome (Nasdaq: IMNM) and Morphimmune announced that they have entered into a definitive merger agreement. The Boards of...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here